Novartis Stock News & Updates
[WKN: 904278 | Symbol: NOT]
Novartis AG: Analyst support could favor the continuation of the trend to new highs
Novartis has evolved into a focused innovation company that concentrates solely on patented, innovative...
Novartis: Cancer Drugs Kisqali and Scemblix Promise Growth of 5-6% per Year until 2030!
Novartis expects strong growth in the coming years due to significantly increased revenue expectations...
Novartis is Planning a $12 Billion Acquisition of Avidity Biosciences to Strengthen RNA Therapeutics
The Swiss pharmaceutical company Novartis (i) has reached a definitive agreement to acquire the U.S....
Novartis Starts a Share Buyback of up to $10 Billion and Raises the Earnings Outlook
Strong performances of recently launched medications demonstrate the replacement power of the portfolio,...
Novartis Combines Stability, Innovation, and Shareholder Friendliness
Since May 2025, Novartis (SIX: NOVN) has been directly listed on German exchanges again. This makes purchases...
Pharmaceutical Stocks are Gaining Momentum: The Defensive Winners of 2025
In times of increased market volatility, pharmaceutical stocks are experiencing a remarkable comeback....
4 Dividend Stocks From Europe for Passive Income
KONE – Robust cash generation drives dividend growth Expected dividend yield: 3.42% The...
Novartis in Pivotal Point Check: Focus on Patented Medications Pays Off – Dividend Increase to CHF 3.50 After Strong Q4!
In the fiscal year 2024, revenue increased by 11% to $50.3 billion. The strategy of focusing on...
- ‹
- 1
- ›